Navigation Links
Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:1/23/2008

-- Peregrine Has Now Received Regulatory Approval for Three Phase II Cancer

Trials to Study Bavituximab in Combination with Chemotherapy -- -- New Clinical Trial Will Evaluate Anti-Tumor Activity of Bavituximab in

Combination with Carboplatin and Paclitaxel --

TUSTIN, Calif., Jan. 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that its Phase II clinical protocol to study bavituximab in combination with chemotherapy in patients with advanced breast cancer has been approved by the Drug Controller General of India (DCGI). The primary objective of the multi-center clinical trial is to assess the overall response rate to the combination of bavituximab with carboplatin and paclitaxel, chemotherapy drugs commonly used in the treatment of breast cancer.

In the trial's two-stage design, up to 15 patients with advanced breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

"We are eager to begin this new trial because we saw encouraging signs of activity against advanced breast cancer in our bavituximab pilot combination therapy study, where two patients treated with bavituximab and these same chemotherapy agents achieved objective tumor r
'/>"/>

SOURCE Peregrine Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009).... 19 BioCryst Pharmaceut...ricing of a public offering of 5,000,000 shares of... gross proceeds of $48.75 million. All of the sha...ffective shelf registration statement previously f... BioCryst has also granted the underwriters a 30-d...
(Date:11/19/2009)... 19 In a series of new i...eska Corporation (Nasdaq: HSKA ) ("Heska" or the ...nd improved website. The upgraded site is the res...ramming to align the site with the company,s new b... http://www.newscom.com/cgi-bin/prnh/20000622/HE...
(Date:11/19/2009)...Nov. 19 Alexza Pharmaceu... its corporate presentation will be webcast live d...nference on Wednesday, December 2, 2009 at 9:00 a.... from The New York Palace Hotel in New York and wi...t and CEO. ,, To access the live presentation...
Breaking Medicine Technology:BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Professor Fisher receives ASEEs Beer and Johnston Award 12942 1ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo Japan 51158 1ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo Japan 51158 2Anti angiogenesis treatment improves hearing in some NF2 patients 51153 1Anti angiogenesis treatment improves hearing in some NF2 patients 51153 2Anti angiogenesis treatment improves hearing in some NF2 patients 51153 3
...,Bulletin Board: PLMO.OB) has announced that its s...-distribution studies on its DFH-12 product,candid...ing of the vascular,system of the lungs., Molecul...ically to,certain parts of the body. In the case o...ond only to the inner walls of the vascular system...
...tion,(Nasdaq: BPUR ) announced today that it has ...ion (FDA) on identifying an acceptable patient,pop...emoglobin glutamer -,250 (bovine)], or HBOC-201. B...tients suffering from Acute Myelogenous Leukemia (... Currently, AML patients who do not,accept blood t...
Other Medicine Technology:Pulmo BioTech Inc. Completes Bio-Distribution Studies 2Pulmo BioTech Inc. Completes Bio-Distribution Studies 3Biopure Announces Meeting With FDA 2Biopure Announces Meeting With FDA 3
(Date:11/21/2009)...Linwood Group ask whether there is a secret to ,al... London, UK (PRWEB) November ...ne in three of the adult UK population drinking en...l-related liver disease*, it is hardly a surprise ...on programmes and residential centres for help. Ho...
(Date:11/20/2009)... Nov. 20 /PRNewswire-FirstCall/ - NUCRYST Pharmace...ng of Shareholders will be held on Monday, Decembe...der approval of two special resolutions. The first...e sale of all or substantially all of the assets o... in the asset purchase agreement dated November 10...
(Date:11/20/2009)..., Nov. 20 The United St...te to make essential changes its health reform bil...n funding and conscience protection on abortion, p...clude strong provisions for adequate affordability...bill an "enormous disappointment" that creates new...
(Date:11/20/2009)...Senators and Congressmen in Competitive Re-electio...re Vote , Washington, DC ...men running for re-election next year in races dee...ok, may come to regret voting for House Speaker Na...a breaking Zogby International/ O’Leary Repo...
(Date:11/20/2009)...0 The American Dental A...g Administration (FDA) to establish appropriate cl..., Citing concern about the safety of whitening pro...fit of professional consultation or examination by...ion of chemically based tooth whitening or bleachi...
Breaking Medicine News(10 mins):Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2
...unged deeper into crisis last night with hospital ...ster Mary Harney’s plans, to recruit 1,300 consult...s Organization (INO) and the Psychiatric Nurses As... the meanwhile, talks between members of the Natio...
...today that the highest quality health care for the... health reforms// that come out of tomorrow’s Coun... Dr Haikerwal said patients would be the big winn...nal boards to run registration and training accred...
...ns and coastal areas is a vital part of the fight ...saster//, according to the IUCN World Conservation...mmunity need to step up marine protection if we ar... The group of the world's leading marine experts ...
...h linked to the superbug Clostridium// difficile (... that causes diarrhea and more serious intestinal ...he number of deaths at the James Paget University ...tatement issued last night, the hospital said four...
...e of insect cells appeared safe and produced an im...search promises to be an alternative to using embr...ine, according to a preliminary study. "All... the use of eggs as the substrate [the base on whi...
... stories on bird flu. After all, it is about the p... that pets may be the only ones who need to be war...ight, an arsenic-based additive that forms an ingr...oyed in chicken feed assists in enhancing growth, ...
Other Medicine News:Health News:Protecting Oceans is Important to Keeping Planet Cool 2Health News:Hospital Infection Deaths Continue in UK 2Health News:Experimental Flu Vaccine Appears Promising in Early Tests 2
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
Medicine Products: